Review

Recent advances in nanotherapeutics for the treatment and prevention of acute kidney injury

Hui Yu, Di Liu, Gaofeng Shu, Feiyang Jin, Yongzhong Du∗

Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

A R T I C L E   I N F O
Article history:
Received 5 April 2020
Revised 7 July 2020
Accepted 22 November 2020
Available online 27 November 2020

A B S T R A C T
Acute kidney injury (AKI) is a serious kidney disease without specific medications currently except for expensive dialysis treatment. Some potential drugs are limited due to their high hydrophobicity, poor in vivo stability, low bioavailability and possible adverse effects. Besides, kidney-targeted drugs are not common and small molecules are cleared too quickly to achieve effective drug concentrations in injured kidneys. These problems limit the development of pharmacological therapy for AKI. Nanotherapeutics based on nanotechnology have been proved to be an emerging and promising treatment strategy for AKI, which may solve the pharmacological therapy dilemma. More and more nanotherapeutics with different physicochemical properties are developed to efficiently deliver drugs, increase accumulation and control release of drugs in injury kidneys and also directly as effective antioxidants. Here, we discuss the recent nanotherapeutics applied in the treatment and prevention of AKI with improved effectiveness and few side effects.

© 2020 Shenyang Pharmaceutical University. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Acute kidney injury (AKI) is a severe kidney disease characterized by a sharp decline in renal function [1], accompanied by high morbidity, medical costs and mortality [2], and is also an important risk factor for chronic kidney disease (CKD) [3]. Among hospitalized patients, AKI is one of the most serious and common complications [4], resulting in approximately 2 million deaths worldwide each year [5]. Currently, there is no reliable drug therapy and clinicians can only rely on expensive generalized supportive care [6,7].

Therefore, it is urgent to develop drugs that are effective for AKI with minimal side effects.

AKI is associated with various etiologies and pathophysiological mechanisms [8], such as ischemia/reperfusion [9,10], sepsis [11,12] and drug toxicity [13,14], as shown in Table 1, and most forms of AKI are characterized by endothelial dysfunction, microcirculation changes, renal tubular damage, and intrarenal inflammation [15]. Oxidative stress is known to be a critical pathogenic factor involved in the initiation, development, and progression of most kidney diseases [16,17]. Specifically, renal hypoxia and ischemia promote the excessive production of reactive oxygen species...
(ROS), which would oxidize and destroy biomolecules and various cell membranes, affect the function of organelle and cause inflammation, renal tubule cell damage, and vascular dysfunction [18].

With the development of mechanistic research, several chemical and biological agents have been proved to have beneficial effects in AKI models [19,20]. However, some potential drugs are highly hydrophobic or easily degradable in vivo, resulting in poor bioavailability, which limits their application in AKI therapy. Besides, kidney-targeted drugs are not common, and most small molecules are easily cleared quickly and can not achieve effective concentrations in injured kidneys. As a result, high doses of drugs are needed, which may cause adverse consequences. Therefore, the current strategy of alleviating AKI is to develop efficient drug delivery systems that can specifically deliver drugs to renal targets and achieve effective concentration with few adverse effects.

Fortunately, the development of nanotechnology-based nanotherapeutics makes this strategy possible. Nanotherapeutics can help improve the bioavailability of drugs, increase the targeting delivery efficiency, and control the drug release [21–25]. The reported nanotherapeutic agents include micelles, liposomes, polymer nanoparticles (NPs), solid lipid NPs, dendrimers, metal NPs, etc., which have been applied in the diagnosis and treatment of various diseases, such as cancer [26,27], Alzheimer’s disease, cardiovascular disease and various inflammations [28]. Nanotherapeutics is also expected to solve the AKI treatment dilemma [29–33]. This review focuses on recently developed nanotherapeutics for AKI prevention and treatment. We discuss nanocarriers that can enhance the bioavailability of potential drugs and renal-target delivery systems that can deliver various drugs specifically into the kidney through passive and active targeting, responsively release cargoes, and lodged in the kidney to exert effects, and certain inorganic NPs studied as therapeutic agents for AKI therapy. Last but not least the potential nephrotoxicity of these nanotherapeutic agents is discussed.

### 2. Nanotherapeutics for acute kidney injury

#### 2.1. Improve the properties of potential drugs

Lots of chemical agents, biological agents and immunotherapy agents, including antioxidants, cytokines, growth factors and microRNAs, have been shown to prevent or alleviate AKI in animal experiments or clinical studies [63–66]. However, due to deficiencies such as poor solubility, in vivo instability, low bioavailability, rapid clearance and possible adverse effects, some agents have limited their application. Therefore, researchers have tried to overcome these problems of agents with nanotechnology and the use of nanomaterials, including lipids, modified biomacromolecules, polymers, to enhance the properties of potential drugs have been proved to be promising [67–69]. Here are some representative examples.

#### 2.1.1. Improved water solubility

Because of the important role of oxidative stress and inflammation in the development of AKI, anti-oxidation and anti-inflammatory have received great attention during the treatment [70]. Flavonoids including eupafolin, curcumin, kaempferol, myricetin, apigenin and luteolin, have excellent anti-oxidant and anti-inflammatory effects [71,72]. However, due to the low water solubility and permeability, flavonoids are extremely limited in the treatment of AKI. Nanocarriers can improve the availability and efficacy of flavonoids [73]. Zhang and colleagues prepared water-soluble eupafolin NPs using polyvinyl alcohol (PVA) and Eudragit E100, which can resolve the physicochemical drawbacks of the original eupafolin, and improve the water solubility by reducing the particle size, with no toxicity to normal renal cells. Eupafolin NPs could inhibit LPS-induced kidney damage with better anti-oxidant and anti-inflammatory activities [40]. Resveratrol is a non-flavonoid polyphenol compound with strong antioxidant capacity but also poor water solubility. Researchers have prepared resveratrol-loaded NPs using polymers, such as poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) polymer and PVP-b-PCL diblock

### Table 1 - Experimental pharmacologic therapies according to the etiology and mechanism of AKI.

| Causes                        | Etiology and mechanism                                                | Experimental pharmacologic therapies                                                                 | Ref. |
|-------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|------|
| Ischemia-reperfusion          | Oxidative stress, Inflammatory reaction, Intracellular Ca²⁺ overload, Renin-angiotensin activation Microcirculation disturbance, Tubular necrosis and apoptosis, Oxidative stress, Renal hemodynamic changes, Toxicity to renal tubular cells and endothelial cells, Imbalance in ROS or nitric oxide production, Inflammation, Renal hemodynamic changes, Coagulation and vascular endothelial dysfunction | Antioxidants (Alpha-lipoic acid, Curcumin, Propofol), Anti-inflammatory Agents, Renin-angiotensin system inhibitor, Apoptosis Inhibitors (Teprasiran (QPI-1002): p53 siRNA) | [6,34–36] |
| Nephrotoxic drugs (e.g., antibiotics, contrast media) | Sepsis                                                                 | Antioxidants (Vitamin C, N-acetylcysteine), Anti-inflammatory Agents (DPP-4 Inhibitors), HMG Co-A reductase inhibitors (Statins) | [6,19] |
|                               |                                                                          | Antioxidants (Resveratrol), Hemodynamic modulators (Angiotensin), Anti-Inflammatory Agents (Reltecomod, Alkaline phosphatase), Antibiotic | [6,37–39] |
| Characteristics                          | Effect                                                                 | Main outcomes                                                                 | Ref. |
|-----------------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------------|------|
| Improve the properties of potential     | Polymers coat water-insoluble molecules                                | Improved water solubility without any toxicity to normal renal cells           |      |
| drugs                                    |                                                                        | Prolonging drug action                                                         |      |
|                                        |                                                                        | Reduced mitochondrial-produced ROS and improved mitochondrial biogenesis and architecture; Ameliorated IRI due to extended mitochondrial protection. |      |
|                                        |                                                                        | Achieved sequential release kinetics with a faster rate of anti-TNF-α and a slower rate of HGF, showed better renal protective potential |      |
| The self-assembling peptide as the     | Hydrogel for biological agents                                        | Enhance in vivo stability of drugs, Controlled release                         |      |
| carrier for mitochondrial protectants   |                                                                        | Cross the GFB and endocytosed by the renal proximal tubules; Amplified the endogenous antioxidant property with the addition of a dinuclear manganese cluster |      |
|                                        |                                                                        |                                                                                |      |
| Specific targeted delivery of drugs to  | Size 5–7 nm                                                            | Pass through the GFB (in the healthy state)                                    |      |
| the kidney                              |                                                                        | Selectively accumulated in injury kidneys and located in renal tubular epithelial cells; Significantly reduced tubular necrosis, less collagen deposition, improved renal fibrosis |      |
|                                        | <100 nm                                                                | Target renal tubule                                                            |      |
|                                        |                                                                        | Resulted in 26-fold renal selectivity and targeted the renal proximal tubular epithelial cells |      |
|                                        | ~400 nm                                                                | Target renal tubule                                                            |      |
|                                        |                                                                        | Kidney-targeted delivery of a selective TLR9 antagonist                        |      |
|                                        | shape fCNTs                                                            | Target renal tubule                                                            |      |
|                                        |                                                                        | ICNT enhanced siRNA delivery to tubule cells and effectively knocked down the expression of several target genes |      |
|                                        | DONs with rectangular, triangular and tubular shapes                   | Target renal tubule                                                            |      |
|                                        | Polymers with negative charge                                          | Accumulate preferentially in the kidneys of healthy mice and AKI mice; Had renal-protective properties |      |
|                                        | Charge Greatest potential of selective accumulation in IR kidney       | • passed through glomerulus and were retained in proximal tubular cells for up to 24 h after injection |      |
|                                        | Integrin Conjugation Anti-E-selectin                                   | Target the inflamed kidney                                                     |      |
|                                        |                                                                        | Efficiently deliver DEX into the inflamed kidney and exhibit a superior capacity to suppress renal inflammation and fibrosis |      |
|                                        | Anti-CD44 Conjugation Anti-E-selectin                                   | Target vascular endothelium                                                    |      |
|                                        |                                                                        | Renal accumulation of DXM is 2.70- and 5.88-fold higher.                       |      |
|                                        | Enzymic-trigger Sensibility pH-responsive                              | Target renal tubular epithelial cells                                          |      |
|                                        | Responsive release                                                     | • Targeted to epithelial cells and relieved oxidative stress damages.          |      |
|                                        |                                                                        | • Enhanced the specific biodistribution and delivery of SS-31, have good effects on reducing oxidative stress and inflammation, preventing tubular apoptosis and necrosis. |      |
|                                        | Innovative NPs                                                        | Scavenge excessive ROS                                                         |      |
|                                        | POM, Ceria, Selenium, BPNS                                              | • Preferential renal uptake and scavenge detrimental ROS to efficiently alleviate clinical symptoms in AKI mice. |      |
|                                        | Mn^{2+}, superparamagnetic iron oxides                                  | • Scavenge ROS and attenuate polymicrobial insult induced an increase in inflammatory mediators and subsequent AKI. |      |
|                                        | MRI, Diagnosis and treatment integration                               | • Protect against AKI development via antioxidant, anti-inflammatory, and anti-apoptotic activities; Exhibited a protective effect in IR-AKI by resisting oxidative stress and inflammation. |      |
|                                        |                                                                        | • Preferably accumulated in kidney and alleviated oxidative-pressure-induced cellular apoptosis. |      |
|                                        |                                                                        | • Preferential renal uptake and a subsequent robust antioxidative response with negligible side effects. |      |

Ref. [40–63]
copolymer, which significantly improved the water solubility of resveratrol and could prevent ischemia/reperfusion renal injury in rats [41,42].

2.1.2. Prolonging drug action
Mitochondrial dysfunction is important in the occurrence and development of AKI [74,75], the biogenesis of mitochondria is critical in the recovery of renal function [76]. Mito-2,2,6,6-tetramethylpiperidine-n-oxyl (tempo) (MT) is an antioxidant against mitochondria that has shown benefits to AKI. However, it has short-term half-life and side effect. To resolve the deficiencies, Zhao et al. developed a carrier based on the self-assembling peptide (SAP) to slowly release MT for longer-term protective effect on AKI. Since MT-loaded SAP has extended mitochondrial protection, it shows a better effect of ameliorating ischemia/reperfusion induced-AKI compared to free MT [43].

2.1.3. Enhance in vivo stability of drugs
Numerous biological agents have been studied in AKI therapy, such as growth factor and antibody. Nanotechnology can be used to achieve controlled release and protect these sensitive cargoes from degradation [77]. In one study, self-assembling peptide/heparin (SAP/Hep) hydrogel was employed to co-deliver hepatocyte growth factor (HGF) and TNF-α neutralizing antibody (anti-TNF-α), which could control the release of two drugs, allowed for a faster release of anti-TNF-α with a sustained release of HGF, prevented two drugs from rapidly degrading in vivo and preserved their bioactivities [44]. This nanoscale delivery platform could achieve effective delivery of two easily degradable drugs and reduce inflammatory and promote tissue repair in the ischemia/reperfusion induced-AKI mice.

2.2. Specific targeted delivery of drugs to the kidney
The need for kidney-targeted drugs is based on the relatively poor pharmacokinetic characteristics, including shorter renal retention time, lower disease site accumulation, and systemic off-target effects [78]. Designing drugs-loaded NPs that can specifically accumulate in the kidneys is a promising strategy to alleviate AKI [79] and the NP-based methods to specifically deliver molecules and increase the retention in the kidney are starting to be explored in animal models.

Due to the strict selectivity of the kidney, only limited nanomaterials and macromolecular are used for kidney-targeted drug delivery, such as poly (vinyl pyrrolidone dimethyl maleic acid copolymer (PVD), polyglutamate, low molecular weight chitosan (LMWC), low molecular weight proteins (LMWP), liposomes, biopolymers, NPs, prodrugs and specific antibodies [30,73,80,81]. The applications of kidney-targeted drug delivery system for AKI therapy will be discussed in detail from two aspects: passive or active targeting in the following section.

2.2.1. Passive target: size, shape and charge
Size: Glomerular filtration membrane has strict size selectivity and NPs with a diameter less than 5–7 nm can easily pass through the glomerular filtration barrier (GFB). Therefore, one strategy is to design small enough NPs to pass through the GFB and then be absorbed by epithelial cells [82]. Uchida and group reported a very small protein-based nanoparticle, a DNA-binding protein (Dps), which is a hollow dodecameric protein cage with putative cytoprotective properties. The diameter of shell is 9 nm and the inner diameter is 5 nm. Dps is easily filtered and could pass through the GFB to reach and accumulate in the proximal tubules [45].

When AKI occurs, the particle size selection of GFB seems to be different. During the occurrence and development of AKI, the glomerular endothelial cell lining and podocyte structure are destroyed. Significant changes in structure and permeability of GFB may allow much larger substances passing through, and these characteristics can be used for the transport of NPs to various renal cells [83–85]. An excellent study has shown that 100 nm poly (lactic-co-glycolic acid) (PLGA) NPs can specifically accumulate in injury kidneys of mice, which is related to the renal injury degree and administration time at the initial stage of ischemia/reperfusion-induced AKI (IR-AKI). NPs were internalized by the epithelial cells of renal tubules with strict particle-size selection. Specifically, 100 nm PLGA NPs accumulate significantly in injured kidneys, while 200 nm and 300 nm PLGA NPs hardly accumulate. Thus 100 nm PLGA oltipraz NPs can selectively target the injured kidneys during the early stage of IR-AKI and continuously release oltipraz to effectively treat AKI [46] (Fig. 1).

Interestingly, the accumulation of drugs in peritubular capillaries seems to have little to do with size, showing distinct absorption characteristics in different parts of the nephron [86]. Unlike the glomerular filtration membrane, which is a physical barrier to NPs, proximal tubules act as a chemical barrier due to their active endocytosis mechanism. A study indicated that NPs with a diameter of 400 nm preferentially localize in the kidney and specifically accumulate in the proximal renal tubules. Since such large NPs are difficult to pass through the GFB, the mechanism may be that NPs are endocytosed by the endothelial cells of the peritubular capillaries, and thereby accumulate in the proximal tubules for a long time [87]. Based on this mechanism, Sang JunHan and colleagues developed a mesoscale nanoparticle-mediated Toll-like receptor 9 (TLR9) antagonist kidney-targeted drug delivery system for ischemia/reperfusion injury (IRI). After intravenous injection, these polymer-based mesoscale NPs with a diameter of 300–400 nm could be localized in the renal tubules to effectively alleviate AKI [48].

Shape: Besides suitable particle size, NPs with special shapes may also be able to pass through the GFB. Ammonium-functionalized single-walled carbon nanotubes (fCNTs) have a very favorable renal glomerular filtration and clearance characteristics [88] and part of filtered fCNTs are reabsorbed at the renal proximal tubular cell brush border and endocytosed [89]. In the cisplatin-induced AKI model, fCNTs with 5-nm diameter were used to deliver drugs to the renal tubules. Compared with the control group, fCNT-mediated delivery increased the siRNA renal accumulation by 10 times, and the portion of the dose that was not delivered to the kidney was quickly eliminated (< 1h) [49] (Fig. 2). In addition to fCNTs, DNA origami nanostructures (DONs) with tubular, triangular and rectangular shapes have also been proved
to preferentially accumulate in kidneys of rhabdomyolysis-induced AKI mice [33].

Charge: In addition to size selectivity, glomerular filtration membrane also has charge selectivity. Endothelial cell glycocalyx, glomerular filtration membrane and podocyte glycocalyx are negatively charged, allowing positively charged NPs to pass through faster than neutral NPs, followed by negatively charged NPs. In one study, a series of fluorescent-labeled polymers with different molecular weights and charges were synthesized to investigate the relationship between renal filtration efficiency and the charge of NPs. The results showed that the polymers with a negative charge and neutral had the greatest potential of selective accumulation in IRI kidney. These polymers pass through the glomeruli and stay in the proximal tubular cells for up to 24 h after injection [50]. However, some studies contradict the general understanding of charge-dependent glomerular filtration, which reported highly negatively charged NPs are cleared faster than less negatively charged NPs [90]. Therefore, further research is required to draw a more general conclusion.
2.2.2. Active targeting: conjugation and sensibility
Active targeted drug delivery systems have gained widespread attention, and researchers try to improve the targeting efficiency by screening for suitable targeting molecules and designing nano-systems with lesion microenvironment responsiveness [90-92]. We will discuss the application of active targeting in AKI therapy from these two aspects.

Conjugation: Compared to NPs with physicochemical properties such as suitable size and charge, NPs conjugated with targeted ligands have higher specificity [32], which is desirable to achieve targeted therapy of diseased cells, and minimize off-target toxicity [93-95]. Megalin and Cubilin, located in the proximal renal tubules, are the major glycoproteins for reabsorption and are also the most concerned receptors for targeting the renal tubule system. So far, multiple targeting ligands have been exploited, including peptides, aptamers, small organic molecules and antibodies. There have been several studies of widely used kidney-targeted peptides, including Epsilon poly-l-lysine-derivatives (εPLL), galectin-3 carbohydrate recognition domain (G3-C12), elastin-like polypeptides (ELPs) and the carrier peptide (KKEEE)3 K [96,97].

In the AKI pathology, a variety of cells, such as inflammation-related cells (e.g. macrophages) and vascular endothelial cells, are activated and undergo a series of changes, which characterized by the expression of specific receptors in most cases. Here, we focus on cases of using these specific receptors to achieve efficient targeted drug delivery.

Microbubble (MV) is a kind of small vesicle that falls off the cell membrane after cell activation, injury or apoptosis. Researchers incubated raw macrophage with dexamethasone (DEX) and then separated MV-DEX from the supernatant by centrifugation. There is an obvious integrin expression pattern on the surface of MV-DEX, in which integrin α 4 β 1 (val-4) and α L β 2 (LFA-1) enable them to target the kidney with inflammation. Therefore, MVs derived from RAW 264.7 macrophage cells can be used as DEX carriers targeting the inflamed kidney efficiently [51]. Compared with conventional DEX treatment, MV-DEX can significantly reduce renal injury, and has enhanced therapeutic effect on nephritis and fibrosis in LPS-induced nephrotic rat model, and significantly reduce side effects of chronic glucocorticoid treatment.

In IR-AKI, E-selectin overexpression on the surface of vascular endothelial cells could be exploited as a promising target for specific-target drug delivery [99]. Hu and colleagues have reported that solid lipid NPs with sialic acid (SA-NPs) as targeting-vascular endothelium carriers for IR-AKI. Cell uptake results indicated that SA-NPs were specifically uptake by inflamed vascular endothelial cells (H2O2-stimulated human umbilical vein endothelial cells), which is related to the specific binding of SA and E-selectin receptors expressed on the inflamed vascular endothelial cells [52]. Furthermore, the biodistribution results showed that SA-NPs increased the accumulation of DXM in kidneys of AKI mice. After 6 h of intravenous injection of SA-NPs, the content of DXM in the kidneys of mice was 5.88 and 2.70 times higher than those injected with NPs and free DXM, respectively (Fig. 3).

During renal IRI, CD44, a transmembrane proteoglycan, is upregulated in injured renal tubular epithelial cells, which is the most important hyaluronic acid (HA) receptor on the cell surface. Based on the inherent characteristics of HA targeting CD44 receptor, Hu et al. developed a polymer prodrug (HA-curcumin, HA-cur) for targeting epithelial cells and the bio-accumulation of HA-cur in the kidney increased by 13.9 times compared to the free curcumin. It is a novel and effective drug delivery system for the application of HA-based polymer prodrugs and has great potential in the treatment of kidney diseases [53]. In another study, Liu and colleagues designed kidney-targeted nanopolyplexes also based on HA targeting CD44 receptor to effectively deliver mitochondrial antioxidant, D-Arg-dimethylTyr-Lys-Phe-NH2 (SS-31). These nanopolyplexes are electrostatically complexed using anionic hyaluronic acid and cationic chitosan as materials, which could be uptake by CD44-overexpressed cells and accumulate in injured areas [54].

Sensibility: Changes of kidney microenvironment, such as excessive ROS, increased enzymatic activity, or lower pH, are expected to be used for drug active targeted delivery. By being
endowed with environmental responsiveness, drug delivery systems can gather more intelligently at the lesion site and release drug specificity. In fact, any design of multifunctional drug nanocarriers should include the function of making the carriers release drugs in the target area and keep stable in the non-target area to ensure treatment efficiency and reduce the systemic side effects [12].

Nano-drug delivery systems or prodrugs that can selectively target kidneys usually release drugs through the action of renal enzymes or the microenvironment changes at the pathological site. For example, based on the overproduction of matrix metalloproteinase-2 (MMP-2) in kidneys during AKI, Hu and his colleagues developed an MMP-2 enzyme-triggered polymerized prodrug. The use of the MMP-2 reactive peptide PVGLIG gives the polymerization prodrg the ability to release curcumin quickly after reaching the target and increases the drug concentration in the target tissue [55]. Besides, since AKI is often associated with acidosis, Yoshitomi et al. designed a pH-responsive nitroxide radical-containing NPs, which could disintegrate within the renal acidic lesion and scavenge excessive ROS to relieve AKI [56].

2.3 Inorganic nanoparticles as antioxidant and contrast agent

In addition to being drug carriers, NPs are also one of the research hotspots as directly effective and low-toxicity drugs. Inorganic NPs have the advantages of excellent thermal stability and biological stability, versatility, easy preparation, and adjustable activity [59], which therefore have been widely used in chemical, biological, and pharmaceutical fields. In recent years, certain inorganic NPs have been applied to various ROS related-diseases, including AKI because of their unique capacity of scavenging ROS, including platinum [100], ceria [101–102], and so on.

Molybdenum can scavenge harmful ROS due to the volatile state of molybdenum ions (between Mo5+ and Mo6+). Dalong Ni and colleagues reported molybdenum-based polyoxometalate (POM) nanoclusters as a new type of nano-antioxidants to protect kidney with preferential renal uptake. The results indicated that with excellent compatibility, these ultrasmall POM nanoclusters (average diameter about 1 nm) had high renal uptake capacity and could efficiently alleviate kidney injury in AKI mice, as confirmed by dynamic PET imaging, renal biomarkers detection, serum tests and kidney tissue staining [57].

Ceria NPs could remove ROS via superoxide dismutase (SOD)-mimetics and catalase (CAT)-mimetics and have regenerated ROS-elimination ability. Manne et al. have investigated the therapeutic efficacy of ceria NPs in the treatment of peritonitis-induced AKI by polymicrobial insult. The results showed that ceria NPs with size between 10–40 nm, could reduce the damage of glomeruli and renal tubules caused by peritonitis, through reaction with excessive ROS in the kidney in vivo [58]. Ceria NPs were
also proved to exhibit a protective effect on cisplatin-induced nephrotoxicity and further research is needed on the potential use of ceria NPs in AKI induced by other factors including sepsis [103].

Selenium is a natural trace element and plays a key role in the activity of several enzymes and proteins, including glutathione peroxidase. In glycerol-induced AKI mice model, selenium NPs could reduce the biochemical, molecular, and histological changes, which suggested that it could prevent the development of AKI through anti-inflammatory, antioxidant and anti-apoptotic activities [59]. In another study, porous Se@SiO$_2$ nanospheres synthesized by nanotechnology could also directly or indirectly scavenge free radicals and ROS in cells to inhibit oxidative stress [60].

Black phosphorus nanosheets (BPNSs) is a new type of two-dimensional material with strong chemical reactivity towards ROS. A research group has designed a new BPNS-based drug delivery platform for AKI therapy. BPNSs has kidney-targeted drug delivery ability because of the same geometrical framework as flake-like DNA and has the capacity of scavenging excessive ROS. Moreover, BPNSs will degrade into phosphorous oxides without any cytotoxicity after treatment. With these advantages simultaneously, BPNSs is promising in AKI therapy [61] (Fig. 4).

In addition to application as antioxidants, inorganic NPs may be more clinically valuable to be used in diagnosis. Early diagnosis of AKI is important for treatment, but it is often difficult. Currently, the diagnosis of AKI is mostly based on the measurement of blood urea nitrogen and creatinine levels, which has numerous problems, including non-specificity and delay rise of these elements [104]. Fortunately, the specific nano-biological interactions and in vivo transport of inorganic NPs that cleared by the kidney provide an opportunity for the detection of early renal diseases, especially, the early detection of dysfunctional renal tubules [105–108]. Nanoparticle-based magnetic resonance imaging (MRI) has been used as a strategy to detect early changes that may be consistent with AKI. One study found that in combination with MRI, dextran-coated iron oxide NPs (HD = 20 nm) can be used for early diagnose of kidney injury while conventional biomarkers, such as creatinine, fail to report [109].

At present, integrated therapy of diagnosis and treatment is more attractive and also under exploration. Tuanwei Sun and colleagues synthesized ultrasmall Mn$^{2+}$-chelated melamin (MMP) NPs through simple coordination and self-assembly strategies, which were further combined with polyethylene glycol (PEG). The final NPs (MMPP) have ultra-small size, good stability, high R1 relaxation, stable radiolabeling performance, and great antioxidative ability. In the mouse AKI model, T1-weighted magnetic resonance (MR) and positron emission tomography (PET) imaging could reveal in vivo circulation of MMPP NPs, and MMPP NPs could efficiently scavenge ROS to alleviate AKI [62] (Fig. 5). In another study, a theranostic nanoparticle for siRNA delivery and multimodal imaging was developed. The core was formed by encapsulation of superparamagnetic iron oxides and indocyanine green in a PLGA matrix and the surface was coated with polyethyleneimine (PEI) for siRNA delivery [63].

### 3. Nephrotoxicity of nanoparticles

The use of NPs provides promising results for AKI pharmacologic therapy. However, the nephrotoxicity of NPs is often a limit of drug delivery, which has not been extensively investigated [104]. Generally, the nephrotoxicity of NPs seems to be closely related to the chemical composition, size, surface charge and functionalization of NPs [110]. And there are disputes over the nephrotoxicity of nanomaterials because different studies may use different types of cells in vitro toxicity tests, routes of exposure and so on. Previous studies have shown that nanomaterials that exhibit excellent renal clearance could avoid the toxicity problems that may result from the long-term accumulation of nanomaterials in the body [89]. Although some studies highlight some of the properties of NPs and how they may affect the kidney, there are no in vivo human studies that particularly investigate the nephrotoxicity of these biological NPs.
4. Conclusions and prospects

In recent years, researchers have made remarkable achievements in the treatment of various diseases based on nanotechnology and increasing preclinical work has also shown its potential in AKI therapy. At present, no specific drugs have been employed to relieve AKI in the clinic, and some potential drugs have been greatly hindered from clinical application by several shortcomings, including low bioavailability rapid clearance and severe systemic side effects. The nanocarriers under research are excellent in improving potential drug properties, increasing bioavailability, selective accumulation, controlling drug release, and reducing systemic side effects, which have shown to significantly improve the efficacy of potential drugs in alleviation AKI in experimental models.

There have been some reviews summarizing the application of nanotechnology in kidney-targeting drug delivery systems, but rarely specifically related to diseased kidney. AKI involves a large number of signal molecules, multiple pathways and different cell types, and its pathological mechanism has not been fully understood so far. Since the pathological mechanism of AKI is very complicated, it is necessary to take the differences compared with healthy kidney into consideration, including changes in filtration, renal tubular reabsorption capacity, and microenvironment. Therefore, we outline the recent nanotherapeutics in AKI, including encapsulation and delivery of water-insoluble molecules and easily degradable agents, employing the filtering characteristics of kidneys in AKI and modification with ligands target to molecules highly expressed under inflammatory condition, such as CD44 to achieve passive and active targeting, as well as inorganic NPs as directly excellent antioxidants and application in the integration of diagnosis and treatment.

Currently, there are no clinically approved kidney-specific nanotherapeutics. But with the further study of the pathogenesis of AKI and the understanding of the mechanism of NPs interaction and transport clearance in the body. We expect to see more and more applications of nanotherapeutics in AKI.

Conflict of interest

The authors report no conflicts of interest.

Acknowledgments

This work was supported by New Century 151 Talent Project of Zhejiang Province, Joint Institute of Lishui Hospital and Zhejiang University for nanomaterials and nanotechnology.

REFERENCES

[1] Mercado MG, Smith DK, Guard EL. Acute kidney injury: diagnosis and management. Am Fam Phys. 2019;100(11):687–94.
[2] Koeze J, Keus F, Dieperink W, van der Horst IC, Zijlstra JG, van Meurs M. Incidence, timing and outcome of AKI in critically ill patients varies with the definition used and the addition of urine output criteria. Bmc Nephrol 2017;18(1):70.
[3] Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012;81(5):442–8.
[4] Murugan R, Kellum JA. Acute kidney injury: what's the prognosis? Nat Rev Nephrol 2011;7(4):209–17.
[5] Luo M, Yang Y, Xu J, Cheng W, Li XW, Tang MM, et al. A new scoring model for the prediction of mortality in patients with acute kidney injury. Sci Rep 2017;7(1):7862.
[6] Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet 2019;394(10212):1949–64.
[7] Mehta RL, Cerda J, Burdmann EA, Tonelli M, Garcia-Garcia G, Jha V, et al. International society of nephrology's Oby25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet 2015;385(9987):2616–43.
[8] Gameiro J, Agapito TJ, Jorge S, Lopes JA. Acute kidney injury definition and diagnosis: a narrative review. J Clin Med 2018;7(10).
[9] Topdaqi O, Tanyeli A, Akdemir F, Ersalan E, Guler MC, Comakli S. Preventive effects of fraxin on ischemia/reperfusion-induced acute kidney injury in rats. Life Sci 2020;242:117217.

[10] Zilberman-Itskovich S, Abu-Hamad R, Stark M, Efrati S. Effect of anti-CS antibody on recuperation from ischemia/reperfusion-induced acute kidney injury. Ren Fail 2019;41(1):967–75.

[11] Rinaldo Bellomo JAKC. Acute kidney injury in sepsis. Intensive Care Med 2017.

[12] Weissig V, Guzman-Villanueva D. Nanocarrier-based antioxidant therapy: promise or delusion? Expert Opin Drug Deliv 2015;12(11):1783–90.

[13] Yuan Y, Zhu L, Li L, Liu J, Chen Y, Cheng J, et al. S-Sulfhydration of SIRT3 by hydrogen sulfide attenuates mitochondrial dysfunction in Cisplatin-Induced acute kidney injury. Antioxid Redox Signal 2019;31(17):1302–19.

[14] Cheng W, Zhao F, Tang CY, Li XW, Luo M, Duan SB. Comparison of iohexol and iodoxanol induced nephrotoxicity, mitochondrial damage and mitochondria in a new contrast-induced acute kidney injury rat model. Arch Toxicol 2018;92(7):2245–57.

[15] Ostermann M, Liu K. Pathophysiology of AKI. Best Pract Res Clin Anaesthesiol 2017;31(3):305–14.

[16] Gorin Y. The kidney: an organ in the front line of oxidative stress-associated pathologies. Antioxid Redox Signal 2016;25(12):639–41.

[17] Tanaka S, Tanaka T, Nagakura M. Hypoxia as a key player in the AKI-to-CKD transition. Am J Physiol Renal Physiol 2014;307(11):F1187–95.

[18] Dennis JM, Witting PK. Protective role for antioxidants in acute kidney disease. Nutrients 2017;9(7).

[19] Yang Y, Song M, Liu Y, Liu H, Sun L, Peng Y, et al. Renoprotective approaches and strategies in acute kidney injury. Pharmacol Ther 2016;163:58–73.

[20] Su X, Xie X, Liu L, Lv J, Song F, Perkovic V, et al. Comparative effectiveness of 12 treatment strategies for preventing contrast-Induced acute kidney injury: a systematic review and bayesian network meta-analysis. Am J Kidney Dis 2017;69(1):69–77.

[21] Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Front Chem 2018;6:360.

[22] Patra JK, Das G, Fraceto LF, Campos E, Rodriguez-Torres M, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 2018;16(1):71.

[23] Choudhury H, Pandey M, Chin PX, Phang YL, Cheah JY, Ooi SC, et al. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. Drug Deliv Transl Res 2018;8(5):1545–63.

[24] Gao X, Guo L, Li J, Thu HE, Hussain Z. Nanomedicines guided nanomaging probes and nanotherapeutics for early detection of lung cancer and abolishing pulmonary metastasis: critical appraisal of newer developments and challenges to clinical transition. J Control Release 2018;292:29–57.

[25] Fang G, Zhang Q, Pang Y, Thu HE, Hussain Z. Nanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: multi-functionalization as an emerging strategy to optimize therapeutic efficacy. J Control Release 2019;303:181–208.

[26] Hussain Z, Arooj M, Malik A, Hussain F, Saadhar H, Khan S, et al. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy. Artif Cells Nanomed Biotechnol 2018;46(sup2):1015–24.

[27] Khan S, Imran M, Butt TT, Shah SWA, Sohail M, Malik A, et al. Curcumin based nanomedicines as efficient nanoplatform for treatment of cancer: new developments in reversing cancer drug resistance, rapid internalization, and improved anticancer efficacy. Trends Food Sci Tech 2018;80:8–22.

[28] Singh AP, Biswas A, Shukla A, Maiti P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct Target Ther 2019;4:33.

[29] Yu M, Xu J, Zheng J. Renal clearable luminescent gold nanoparticles: from the bench to the clinic. Angew Chem Int Ed Engl 2019;58(13):4112–28.

[30] Zhou P, Sun X, Zhang Z. Kidney-targeted drug delivery systems. Acta Pharm Sin B 2014;4(1):37–42.

[31] He Z, Tang H, You X, Huang K, Dhinakar A, Kang Y, et al. BAPTA-AM nanoparticle for the curing of acute kidney injury induced by ischemia/reperfusion. J Biomed Nanotechnol 2018;14(5):868–83.

[32] Nam J, Won N, Bang J, Jin H, Park J, Jung S, et al. Surface engineering of inorganic nanoparticles for imaging and therapy. Adv Drug Deliv Rev 2013;65(5):622–48.

[33] Jiang D, Ge Z, Im H, England CG, Ni D, Hou J, et al. DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury. Nat Biomed Eng 2018;2(11):865–77.

[34] Seif B, Kakkadhadee M, Bakshi E, Ranjanbar M, Aghhari P, Bastebar T. Enhancement of renal oxidative stress by injection of angiotensin II into the paraventricular nucleus of renal ischemia-reperfusion injury. Can J Physiol Pharmacol 2014;92(9):752–7.

[35] Hulse M, Rosner MH. Drugs in development for acute kidney injury. Drugs 2019;79(8):811–21.

[36] Chen H, Busse IW. Novel therapies for acute kidney injury. Kidney Int Rep 2017;2(5):785–99.

[37] Baghshaw SM, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood G, et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med 2009;35(5):871–81.

[38] Peerpornratana S, Manrique-Caballero CL, Gomez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int 2019;96(5):1083–99.

[39] Luo JC, Qiu KH, Pan C, Xie JF, Yu T, Liu L, et al. Increased cardiac index attenuates septic acute kidney injury: a prospective observational study. BMC Anesthesiol 2015;15:22.

[40] Zhang H, Chen MK, Li K, Hu C, Lu MH, Situ J. Eupafolin nanoparticle improves acute renal injury induced by LPS through inhibiting ROS and inflammation. Biomed Pharmacothe 2017;85:704–11.

[41] Li HL, Yan Z, Ke ZP, Tian XF, Zhong LL, Lin YT, et al. IGFBP2 is a potential biomarker in acute kidney injury (AKI) and resveratrol-loaded nanoparticles prevent AKI. Oncotarget 2018;9(93):36551–60.

[42] Xu Y, Zhang B, Xie D, Hu Y, Li HL, Zhong L, et al. Nanoparticle-mediated dual delivery of resveratrol and DAP5 ameliorates kidney ischemia/reperfusion injury by inhibiting cell apoptosis and inflammation. Oncotarget 2017;8(24):39547–58.

[43] Zhao M, Zhou Y, Liu S, Li L, Chen Y, Cheng J, et al. Control release of mitochondria-targeted antioxidant by injectable self-assembling peptide hydrogel ameliorates persistent mitochondrial dysfunction and inflammation after acute kidney injury. Drug Deliv 2018;25(1):546–54.

[44] Liu S, Zhao M, Zhou Y, Li L, Wang C, Yuan Y, et al. A self-assembling peptide hydrogel-based drug co-delivery
platform to improve tissue repair after ischemia-reperfusion injury. Acta Mater 2019.

[45] Uchida M, Maier B, Waghwani HK, Selivanovitch E, Pay SL, Avera J, et al. The archael Dps nanocage targets kidney proximal tubules via glomerular filtration. J Clin Invest 2019;129(9):3941–51.

[46] Yu H, Lin T, Chen W, Cao W, Zhang C, Wang T, et al. Size and temporal-dependent efficacy of oltipraz-loaded PLGA nanoparticles for treatment of acute kidney injury and fibrosis. Biomaterials 2019;219:119368.

[47] Williams RM, Shah J, Ng BD, Minton DR, Gudas LJ, Park CY, et al. Mesoscale nanoparticles selectively target the renal proximal tubule epithelium. Nano Lett 2015;15(4):2358–64.

[48] Han SJ, Williams RM, Agati VD, Jaimes EA, Heller DA, Lee HT, et al. Selective nanoparticle-mediated targeting of renal tubular Toll-like receptor 9 attenuates ischemic acute kidney injury. Kidney Int 2020;98(1):76–84.

[49] Alidori S, Akhavein N, Thorek DL, Behling K, Romin Y, Queen D, et al. Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci Transl Med 2016;8(331):331r–9r.

[50] Chen Y, Tang W, Yu F, Xie Y, Jaramillo I, Jiang HS, et al. Determinants of preferential renal accumulation of synthetic polymers in acute kidney injury. Int J Pharm 2019;568:118555.

[51] Tang TT, Lv LL, Wang B, Cao JY, Feng Y, Li ZL, et al. Employing macrophage-derived microvesicle for kidney-targeted delivery of dexamethasone: an efficient therapeutic strategy against renal inflammation and fibrosis. Theranostics 2019;9(16):4740–55.

[52] Hu JB, Song GL, Liu D, Li SJ, Wu JH, Kang XQ, et al. Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury. Drug Deliv 2017;24(1):1856–67.

[53] Hu JB, Li SJ, Kang XQ, Qi J, Wu JH, Wang XJ, et al. CD44-targeted hyaluronic acid-curcumin prodrug protects renal tubular epithelial cell survival from oxidative stress damage. Carbohydr Polym 2018;193:268–80.

[54] Liu D, Jin F, Shu G, Xu X, Qi J, Kang X, et al. Enhanced efficency of echondria-targeted peptide SS-S3 for acute kidney injury by pH-responsive and AKI-kidney targeted nanopolyplexes. Biomaterials 2019;211:57–67.

[55] Hu JB, Liu D, Qi J, Lu KJ, Jin FY, Ying XY, et al. An E-selectin targeting and MMP-2-responsive dextran-curcumin polymeric prodrug for targeted therapy of acute kidney injury. Biomater Sci 2018;6(12):3397–409.

[56] Yoshitomi T, Hirayama A, Nagasaki Y. The ROS scavenging and renal protective effects of pH-responsive nitrooxide radical-containing nanoparticles. Biomaterials 2011;32(31):8021–8.

[57] Ni D, Jiang D, Kutyreff CJ, Lai J, Yan Y, Barnhart TE, et al. Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nat Commun 2018;9(1).

[58] Manne ND, Aravalli R, Nepal N, Shokufar T, Rice KM, Asano S. Cerium oxide nanoparticles attenuate acute kidney injury induced by intra-abdominal infection in Sprague-Dawley rats. J Nanobiotechnol 2015;13:75.

[59] AlBasher G, Alfarraj S, Alarifi S, Alkhnati S, Almeir R, AlSalut N, et al. Nephroprotective role of selenium nanoparticles against Glycerol-Induced acute kidney injury in rats. Biol Trace Elem Res 2019.

[60] Zheng Z, Deng G, Qi C, Xu Y, Liu X, Zhao Z, et al. Porous Se@SiO2 nanospheres attenuate ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) and inflammation by antioxidative stress. Int J Nanomedicine 2019;14:215–29.

[61] Hou J, Wang H, Ge Z, Zuo T, Chen Q, Liu X, et al. Treating acute kidney injury with antioxidative black phosphorus nanosheets. Nano Lett 2020;20(2):1447–54.

[62] Sun T, Jiang D, Rosenkrans ZT, Ehlerding EB, Ni D, Qi C, et al. A melanin-based natural antioxidant defense nanosystem for theranostic application in acute kidney injury. Adv Funct Mater 2019;29(48):1904833.

[63] Yang C, Hieu V, Huum DMU, Tingskov SJ, Vinding MS, Nielsen T, et al. Theranostic poly(actic-co-glycolic acid) nanoparticle for magnetic resonance/infrared fluorescence bimodal imaging and efficient siRNA delivery to macrophages and its evaluation in a kidney injury model. Nanomed-Nanotechnol 2017;13(8):2451–62.

[64] Gomez-Sierra T, Eugenio-Perez D, Sanchez-Chinchillas A, Pedraza-Chaverri J. Role of food-derived antioxidants against cisplatin induced-nephrotoxicity. Food Chem Toxicol 2018;120:230–42.

[65] Stoppе C, Averdunk L, Goetzenich A, Soppert J, Marlier A, Kraemer S, et al. The protective role of macrophage migration inhibitory factor in acute kidney injury after cardiac surgery. Transl Med 2018;10(441).

[66] Fan PC, Chen CC, Chen YC, Chang YS, Chu PH. MicroRNAs in acute kidney injury. Hum Genomics 2016;10(1):29.

[67] Soriano ML, Rodriguez-Benot A, Valcarcel M. Nanotechnological foundations of a new nephrology. Nefrologia 2018;38(4):368–78.

[68] Xu Y, Hu N, Jiang W, Yuan HF, Zheng DH. Curcumin-carrying nanoparticles prevent ischemia-reperfusion injury in human renal cells. Oncotarget 2016;7(52):87390–401.

[69] Holthoff JH, Wang Z, Seely KA, Goldner N, Mayeux PR. Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int 2012;81(4):370–8.

[70] Pavlakou F, Liakopoulos V, Eleftheriadis T, Mitsis M, Dounoussi E. Oxidative stress and acute kidney injury in critical illness: pathophysiological mechanisms-biomarkers-interventions, and future perspectives. Oxid Med Cell Longev 2017;2017:6193694.

[71] Ginwala R, Bhavsar R, Chigbu DI, Jain P, Khan ZK. Potential role of flavonoids in preventing chronic inflammatory diseases with a special focus on the anti-inflammatory activity of apigenin. Antioxidants (Basel) 2019;8(2).

[72] Dai X, Liu J, Zheng H, Wichmann J, Hopfner U, Sudhop S, et al. Nano-formulated curcumin accelerates acute wound healing through Dkk-1-mediated fibroblast mobilization and MCP-1-mediated anti-inflammation. Npg Asia Mater 2017;9(3):e368.

[73] Cordoba-David G, Duro-Castano A, Castelo–Branco RC, Gonzalez-Guerrero C, Cannata P, Sanz AB, et al. Efferent nephroprotection against acute kidney injury with a star-shaped polyglutamate-curcuminoid conjugate. Sci Rep 2020;10(1):2056.

[74] Emma F, Montini G, Parikh SM, Salviati L. Mitochondrial dysfunction in inherited renal disease and acute kidney injury. Nat Rev Nephrol 2016;12(5):267–80.

[75] Kezic A, Spasojevic I, Lezaic V, Bajecic M. Mitochondria-targeted antioxidants: future perspectives in kidney ischemia reperfusion injury. Oxd Med Cell Longev 2016;2016:2950503.

[76] Mukhopadhyay P, Horvath B, Zsengeller Z, Zielonka J, Tanchian G, Golovac E, et al. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic Biol Med 2012;52(2):497–506.

[77] Yin HJ, Kim DS, Chung HC, Shing B, Moon KH, George SK, et al. Controlled delivery of stem cell-derived trophic factors accelerates kidney repair after renal
ischemia-reperfusion injury in rats. Stem Cells Transl Med 2019;8(9):959–70.

[78] Williams RM, Shah J, Tian HS, Chen X, Geissmann F, Jaimes EA, et al. Selective nanoparticle targeting of the renal tubules. Hypertension 2018;71(1):87–94.

[79] Yu H, Jin F, Liu D, Shu G, Wang X, Qi J, et al. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury. Theranostics 2020;10(5):2342–57.

[80] Eirin A. Hitching a ride to renal repair. Am J Physiol Renal Physiol 2017;312(2):F276–7.

[81] McGarraughty S, Davis-Taber RA, Zhu CZ, Cole TB, Nikkel AL, Chhaya M, et al. Targeting anti-TGF-beta therapy to fibrotic kidneys with a dual specificity antibody approach. J Am Soc Nephrol 2017;28(12):3616–26.

[82] Williams RM, Jaimes EA, Heller DA. Nanomedicines for kidney diseases. Kidney Int 2016;90(4):740–5.

[83] Kamaly N, He JC, Ausiello DA, Farokhzad OC. Nanomedicines for renal disease: current status and future applications. Nat Rev Nephrol 2016;12(12):738–53.

[84] Andersson M, Nilsson U, Hjalmarsson C, Haraldsson B, Nyström JS. Mild renal ischemia-reperfusion reduces charge and size selectivity of the glomerular barrier. Am J Physiol Renal Physiol 2007;292(6):F1802–9.

[85] Rippe C, Rippe A, Larsson A, Asegirossen D, Rippe B. Nature of glomerular capillary permeability changes following acute renal ischemia-reperfusion injury in rats. Am J Physiol Renal Physiol 2006;291(6):F1362–8.

[86] Naumenko V, Nikitin A, Kapitanova K, Melnikov P, Vodopyanov S, Garanina A, et al. Intravital microscopy reveals a novel mechanism of nanoparticles excretion in kidney. J Control Release 2019;307:368–78.

[87] McDevitt MR, Chattopadhyay D, Jaggi JS, Finn RD, Zannonico PB, Villa C, et al. PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS ONE 2007;2(9):e907.

[88] Ruggiero A, Villa CH, Bander E, Rey DA, Berkvist M, Batt CA, et al. Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci USA 2010;107(27):12369–74.

[89] Du B, Yu M, Zheng J. Transport and interactions of nanoparticles in the kidneys. Nat Rev Mater 2018;3(10):358–74.

[90] Dolman ME, Harmsen S, Storm G, Hennink WE, Kok RJ. Drug targeting to the kidney: advances in the active targeting of therapeutics to proximal tubular cells. Adv Drug Deliv Rev 2010;62(14):1344–57.

[91] Guo X, Cheng Y, Zhao X, Luo Y, Chen J, Yuan WE. Advances in redox-responsive drug delivery systems of tumor microenvironment. J Nanobiotechnol 2018;16(1):74.

[92] Shahriari M, Zahiri M, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M. Enzyme responsive drug delivery systems in cancer treatment. J Control Release 2019;308:172–89.

[93] Wang J, Masehi-Lano J, Chung EJ. Peptide and antibody ligands for renal targeting nanomedicine strategies for kidney disease. Biomater Sci 2017;5(8):1450–9.

[94] Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014;66:2–25.

[95] Geng Q, Sun X, Gong T, Zhang ZR. Peptide-drug conjugate linked via a disulfide bond for kidney targeted drug delivery. Bioconjug Chem 2012;23(6):1200–10.

[96] Bidwell GR, Mahdi F, Shao Q, Logue OC, Waller JP, Reese C, et al. A kidney-selective biopolymer for targeted drug delivery. Am J Physiol Renal Physiol 2017;312(1):F54–64.

[97] Wang J, Poon C, Chin D, Milkowski S, Lu V, Hallows KR, et al. Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery. Nano Res 2018;11(10):5584–95.

[98] Hu JB, Kang XQ, Liang J, Wang XJ, Xu XL, Yang P, et al. E-selectin-targeted sialic acid-Fcγ-dexamethasone micelles for enhanced anti-Inflammatory efficacy for acute kidney injury. Theranostics 2017;7(8):2204–19.

[99] Ferreira CA, Ni D, Rosenkrans ZT, Cai W. Scavenging of reactive oxygen and nitrogen species with nanomaterials. Nano Res 2018;11(10):4955–84.

[100] Watanabe A, Kajita M, Kim J, Kanayama A, Takahashi K, Mashino T, et al. In vitro free radical scavenging activity of platinum nanoparticles. Nanotechnology 2009;20(45):455105.

[101] Kim CK, Kim T, Choi YJ, Soh M, Kim D, Kim YJ, et al. Ceria nanoparticles that can protect against ischemic stroke. Angew Chem Int Ed Engl 2012;51(44):11039–43.

[102] Soh M, Kang DW, Jeong HG, Kim D, Kim DY, Yang W, et al. Ceria-Zirconia nanoparticles as an enhanced multi-Antioxidant for sepsis treatment. Angew Chem Int Ed Engl 2017;56(38):11399–403.

[103] Saifi MA, Sangolma S, Khurana A, Godugu C. Protective effect of nanoceria on cisplatin-induced nephrotoxicity by amelioration of oxidative stress and pro-inflammatory mechanisms. Biol Trace Elem Res 2019;189(1):145–56.

[104] Brede C, Labhasetwar V. Applications of nanoparticles in the detection and treatment of kidney diseases. Adv Chronic Kidney Dis 2013;20(6):454–65.

[105] Kobayashi H, Jo SK, Kawamoto S, Yasuda H, Hu X, Knopp MV, et al. Polyamine dendrimer-based MRI contrast agents for functional kidney imaging to diagnose acute renal failure. J Magn Reson Imaging 2004;20(3):512–18.

[106] Yu M, Liu J, Ning X, Zheng J. High-contrast noninvasive imaging of kidney clearance kinetics enabled by renal clearable nanohyperphores. Angew Chem Int Ed Engl 2015;54(51):15343–8.

[107] Yu M, Zhou J, Du B, Ning X, Atumeh C, Gandel L, et al. Noninvasive staging of kidney dysfunction enabled by renal-clearable luminescent gold nanoparticles. Angew Chem Int Ed Engl 2016;55(8):2787–91.

[108] Xu J, Yu M, Carter P, Hernandez E, Dang A, Kapur P, et al. In vivo x-ray imaging of transport of renal clearable gold nanoparticles in the kidneys. Angew Chem Int Ed Engl 2017;56(43):13356–60.

[109] Laisys JP, Idee JM, Loshkajian A, Benderbous S, Chillon S, Beaufils H. Reversibility of experimental acute renal failure in rats: assessment with USPIO-enhanced MR imaging. J Magn Reson Imaging 2000;12(2):278–88.

[110] Javcic I, Fontana L, Nordberg G. The effects of nanoparticles on the renal system. Crit Rev Toxicol 2016;46(6):490–560.